What is Femara (letrozole)?
Femara, the brand name for letrozole, is an oral aromatase inhibitor. It reduces estrogen levels by blocking the aromatase enzyme that converts androgens into estrogens in peripheral tissues. Because many breast cancers depend on estrogen for growth, lowering estrogen can slow tumor progression and reduce recurrence after surgery. Femara is commonly used as adjuvant therapy following surgery/radiation, as extended adjuvant therapy after tamoxifen, and for metastatic hormone receptor–positive disease. Outside oncology, clinicians sometimes prescribe letrozole off label for ovulation induction in selected infertility scenarios due to its effect on follicle-stimulating hormone dynamics. While effective, it remains a prescription medicine that should be started and monitored by a qualified healthcare professional.
Common uses of Femara
In breast cancer, Femara is primarily indicated for postmenopausal women with estrogen receptor–positive (ER+) or hormone receptor–positive (HR+) disease. Typical applications include adjuvant therapy to reduce recurrence after definitive surgery; extended adjuvant therapy to continue protection after completing tamoxifen; and first-line or subsequent therapy for metastatic disease. In these settings, letrozole has demonstrated improvements in disease-free survival and, in some contexts, overall survival. It may also be used alongside ovarian suppression in premenopausal patients under specialist care when an aromatase inhibitor strategy is preferred.
Off label, letrozole is used for ovulation induction in patients with anovulatory infertility or in certain assisted reproduction protocols. Compared with clomiphene, some evidence suggests letrozole may yield higher ovulation or live-birth rates in defined populations and may reduce antiestrogenic effects on the endometrium. This fertility use is not FDA-approved; it must be individualized and timed within the menstrual cycle by a fertility specialist, with pregnancy testing prior to each cycle to avoid exposure during pregnancy.
How Femara works (aromatase inhibitor mechanism)
Aromatase converts androgens (from the adrenal glands and, in postmenopausal women, also from the ovaries before menopause) into estrogens in fat, muscle, and other tissues. Femara binds the aromatase enzyme and inhibits this conversion, sharply lowering circulating estradiol and estrone. For HR+ breast cancers, less estrogen means fewer receptor-mediated signals driving growth and survival. In fertility induction, transient suppression of estrogen lifts negative feedback on the hypothalamic-pituitary axis, increasing gonadotropin release to stimulate follicular development. These opposite clinical goals—sustained estrogen suppression in cancer versus short, cycle-specific use in infertility—underscore why precise dosing and monitoring are essential.
Dosage and direction
For breast cancer, the usual adult dose of Femara is 2.5 mg by mouth once daily, with or without food, at the same time each day. Adjuvant therapy is often continued for at least 5 years, and some patients may benefit from extended therapy based on recurrence risk and tolerability. In metastatic disease, treatment continues until disease progression or unacceptable toxicity. Renal impairment generally does not require dose adjustment if kidney function is above severe thresholds; significant hepatic impairment warrants caution and specialist guidance. Never adjust or stop therapy without consulting your oncology team.
For ovulation induction, letrozole is used off label in short courses, commonly started early in the cycle (for example, days 3–7), with dosing regimens that vary by clinic protocol and patient response. Because it is not an FDA-approved fertility indication, this use should be supervised by a reproductive endocrinologist who can tailor dose, timing, and monitoring (ultrasound, hormone levels) to optimize safety and success. Self-directed dosing or unsupervised cycle manipulation is unsafe and discouraged.
Precautions and monitoring
Femara’s estrogen-lowering effect can reduce bone mineral density over time. Baseline and periodic bone health assessments (DEXA scans) are recommended, with attention to calcium/vitamin D intake, weight-bearing exercise, and, when appropriate, bone-protective therapy. Lipid profiles may change during therapy; periodic cholesterol monitoring and cardiovascular risk management are advisable. Liver enzymes can rise in some patients, so clinicians may check hepatic function at baseline and intermittently, especially if symptoms or comorbidities are present. Dizziness or fatigue can occur; caution is warranted when driving or operating machinery until you understand your response.
Reproductive considerations are crucial. Letrozole is contraindicated in pregnancy and not recommended during breastfeeding. Effective contraception is essential during cancer treatment and for a period after the last dose as advised by your clinician. In fertility cycles, a negative pregnancy test before starting each course is standard, and exposure should be avoided once pregnancy occurs. Patients with a history of osteoporosis, significant liver disease, or uncontrolled cardiovascular risk factors should discuss the risk–benefit profile thoroughly with their healthcare provider before initiating Femara.
Contraindications
Femara is contraindicated in pregnancy due to potential fetal harm and is not indicated during breastfeeding. Do not use letrozole if you have a known hypersensitivity to letrozole or any tablet component. It is generally intended for postmenopausal women; premenopausal use for cancer typically requires concurrent ovarian suppression under specialist supervision. Severe hepatic impairment demands caution; clinicians may modify therapy or select alternatives depending on risk. For fertility induction, letrozole should not be taken if pregnant, and treatment should be directed by a specialist to avoid inappropriate exposure and timing errors.
Possible side effects
Common adverse effects include hot flashes, night sweats, joint or muscle pain (arthralgia/myalgia), fatigue, headache, dizziness, nausea, edema, and sleep disturbances. Vaginal dryness, decreased libido, and mood changes can occur. Because estrogen supports bone maintenance, long-term therapy may contribute to osteopenia or osteoporosis and increase fracture risk. Some patients experience elevated cholesterol or changes in blood pressure. Many effects are manageable with lifestyle measures or supportive medications; report persistent or bothersome symptoms to your care team promptly.
Less common but important effects include carpal tunnel syndrome, skin rash, and liver enzyme elevations. Seek urgent care for signs of serious reactions, such as marked shortness of breath, chest pain, severe abdominal pain, jaundice, unusual bleeding, or severe allergic reactions (facial swelling, hives, difficulty breathing). Oncology teams often coordinate symptom management strategies—ranging from exercise and physical therapy for joint pain to pharmacologic options—to keep patients on effective therapy while maintaining quality of life.
Drug interactions
Avoid taking tamoxifen or estrogen-containing therapies (including many hormone replacement products) with Femara, as they can diminish its therapeutic effect. Letrozole is metabolized via CYP3A4 and CYP2A6; strong enzyme inducers (such as rifampin, carbamazepine, phenytoin, or St. John’s wort) may reduce letrozole levels, whereas potent inhibitors could theoretically increase exposure. Always provide your clinician and pharmacist with a complete medication and supplement list. While clinically significant interactions are not extensive, coordination is key—especially with anticoagulants, lipid-lowering drugs, and agents that affect bone or liver health.
Missed dose
If you miss a dose of Femara and it has been only a few hours, take it as soon as you remember. If it is close to your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double up to “catch up,” as this increases the risk of side effects without improving efficacy. If missed doses become frequent, contact your care team for adherence strategies that fit your daily routine.
Overdose
There is no specific antidote for letrozole overdose. If you take more than prescribed, seek immediate medical attention or contact poison control. Supportive care—monitoring vital signs, managing symptoms such as dizziness, nausea, or vomiting, and ensuring hydration—is typically employed. Bring your medication container to help clinicians quickly identify the dose taken and provide appropriate care.
Storage
Store Femara tablets at room temperature (generally 68–77°F or 20–25°C), away from moisture, heat, and direct light. Keep the medication in its original, tightly closed container and out of reach of children and pets. Do not store in the bathroom. Safely discard expired or unused tablets according to local guidance or through take-back programs recommended by your pharmacist.
U.S. sale and prescription policy
In the United States, Femara (letrozole) is a prescription-only medication. Federal and state laws require that dispensing occur pursuant to a valid prescription issued by a licensed clinician after an appropriate evaluation. While online purchasing is convenient, it must remain compliant: avoid websites that offer to sell prescription drugs without clinician oversight, as these may be unsafe, illegal, or supply substandard products.
HealthSouth Hospital of Gadsden offers a legal and structured solution for individuals who do not already have a prescription in hand. Through a compliant process—such as pharmacist consultation and, where permitted, coordination with licensed telehealth providers—eligible patients can undergo an appropriate review, and a prescription may be issued if medically suitable. This preserves safety, documentation, and supply-chain integrity while enabling convenient access to Femara. Pricing transparency, identity verification, secure shipping, and U.S.-sourced products support both clinical quality and consumer protection. Always use Femara under the supervision of a qualified healthcare professional and in accordance with U.S. regulations.
